How does Quiviviq (daridorexant) differ from Dayvigo (lemborexant)?

Quiviviq (Daridorexant) vs. Dayvigo (Lemborexant): Key Differences

Lemborexant (Dayvigo) demonstrates superior efficacy for sleep maintenance with greater reductions in wake after sleep onset (-45 minutes vs -13 minutes), but daridorexant (Quiviviq) offers a more favorable safety profile with significantly lower rates of daytime somnolence.

Mechanism & Pharmacology

Both are dual orexin receptor antagonists (DORAs) that block OX1R and OX2R receptors to suppress wake drive 11. However, they differ in:

• Half-life: Lemborexant has a longer elimination half-life, providing more sustained overnight coverage but potentially increasing next-day effects 2
• Receptor binding: Both bind competitively to orexin receptors, but lemborexant's active metabolite (M10) maintains comparable receptor affinity to the parent drug 1

Efficacy Differences

Sleep Maintenance (WASO - Wake After Sleep Onset)

• Lemborexant: Reduces WASO by approximately 45 minutes compared to placebo 34
• Daridorexant: Reduces WASO by approximately 13 minutes compared to placebo 34

Lemborexant is substantially more effective for sleep maintenance problems.

Sleep Onset (Sleep Latency)

• Lemborexant: Reduces subjective sleep onset latency by 25 minutes 3
• Daridorexant: Reduces subjective sleep onset latency by 2.3 minutes (not statistically significant) 3

Lemborexant is more effective for difficulty falling asleep.

Total Sleep Time

• Lemborexant 10mg: Improves total sleep time with clinically meaningful effect sizes (NNT <10) 5
• Daridorexant 25mg: Shows more modest improvements (NNT ≥10), with the 50mg dose performing better 5

Dose-Response Patterns

• Lemborexant: Consistent efficacy across 5mg and 10mg doses 34
• Daridorexant: Clear dose-dependent effect; 50mg significantly outperforms 25mg 3

Safety & Tolerability Profile

Daytime Somnolence (Critical Difference)

• Lemborexant: 5.6-fold higher risk of somnolence vs placebo (5-8% incidence) 6637
• Daridorexant: 1.55-fold risk (not statistically significant vs placebo) 37

This is the most clinically significant safety distinction—daridorexant causes substantially less next-day drowsiness.

Treatment-Emergent Adverse Events (TEAEs)

• Lemborexant: No significant increase in overall TEAEs vs placebo (RR 1.21, p=0.08) 3
• Daridorexant: Higher overall TEAE rates vs placebo (RR 1.16, p=0.01), particularly at 25mg dose 3

Respiratory Safety

• Daridorexant: Significantly lower risk of severe dyspnea compared to lemborexant 4
• Both have been studied in mild-moderate COPD, but lemborexant lacks data in severe COPD (FEV1 <30%) 1

Discontinuation Rates

• Lemborexant: Low discontinuation due to adverse events; somnolence rarely leads to stopping 85
• Daridorexant: Paradoxically, placebo had higher discontinuation rates than active drug at month 3 5

Clinical Decision Algorithm

For sleep maintenance insomnia (frequent nighttime awakenings, prolonged WASO):

• Choose lemborexant 10mg if patient can tolerate potential next-day drowsiness and needs robust efficacy 34
• Start 5mg if concerned about tolerability

For sleep onset insomnia (difficulty falling asleep):

• Choose lemborexant 10mg as first-line; daridorexant shows minimal benefit for sleep onset 34

For patients requiring minimal next-day impairment:

• Choose daridorexant 50mg (not 25mg—dose matters significantly) 35
• Particularly important for elderly, those who drive/operate machinery, or with fall risk

For patients with respiratory concerns:

• Prefer daridorexant due to lower dyspnea risk 4

For overall poor sleep efficiency:

• Choose lemborexant for broader spectrum improvement 4

Important Caveats

Abuse Potential

Both are Schedule IV controlled substances. Lemborexant produces subjective effects similar to zolpidem and suvorexant in recreational sedative users 1. Neither produces physical dependence or withdrawal symptoms 1.

FDA Warnings (Both Drugs)

• Complex sleep behaviors (sleep-driving)
• Cognitive/behavioral changes, amnesia, hallucinations
• Worsening depression/suicidal ideation in depressed patients
• Sleep paralysis and hypnagogic/hypnopompic hallucinations 661

Food Effects

Lemborexant absorption is delayed 2 hours and Cmax reduced 23% with high-fat meals 1. Take on empty stomach or light meal for optimal effect.

Evidence Quality

The available guidelines 888 predate both lemborexant and daridorexant approval, only covering suvorexant (the first DORA). The comparative data comes from indirect comparisons and network meta-analyses 375, not head-to-head trials.

Bottom Line

Lemborexant wins on efficacy; daridorexant wins on daytime safety. The choice depends on whether your priority is maximizing sleep improvement (lemborexant) or minimizing next-day impairment (daridorexant). For most patients with significant sleep maintenance problems who can tolerate mild somnolence, lemborexant 10mg is the more effective choice. For patients requiring alertness or with fall/respiratory concerns, daridorexant 50mg is safer 375.